Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
6.52
-0.11 (-1.66%)
At close: Sep 16, 2025, 4:00 PM EDT
6.80
+0.28 (4.29%)
After-hours: Sep 16, 2025, 6:23 PM EDT
Evolus Revenue
Evolus had revenue of $69.39M in the quarter ending June 30, 2025, with 3.70% growth. This brings the company's revenue in the last twelve months to $277.94M, up 17.15% year-over-year. In the year 2024, Evolus had annual revenue of $266.27M with 31.76% growth.
Revenue (ttm)
$277.94M
Revenue Growth
+17.15%
P/S Ratio
1.49
Revenue / Employee
$837,172
Employees
332
Market Cap
421.75M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 266.27M | 64.19M | 31.76% |
Dec 31, 2023 | 202.09M | 53.47M | 35.98% |
Dec 31, 2022 | 148.62M | 48.94M | 49.10% |
Dec 31, 2021 | 99.67M | 43.13M | 76.29% |
Dec 31, 2020 | 56.54M | 21.62M | 61.89% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EOLS News
- 4 days ago - Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 8 days ago - Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer - Business Wire
- 22 days ago - Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp - Business Wire
- 27 days ago - Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product - Business Wire
- 5 weeks ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 6 weeks ago - Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins - Business Wire